Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK)

Fig. 1

Disease activity per protocol. a The proportion of patients in low disease activity (LDA) was depicted with the 95 % confidence interval (CI) as an error bar. The interval of the intravenous (IV) abatacept between days 0 and 28 is marked with a bar. Before and after this time frame, the patient was treated with subcutaneous (SC) abatacept. b The mean disease activity score in 28 joints (DAS-28) was depicted for all patients with the standard deviation (SD) as error bars. c The mean health assessment questionnaire disability index (HAQ-DI) was depicted for all patients with the SD as error bars. d The mean DAS-28 was depicted for patients pre-exposed to tumor necrosis factor (TNF) antagonists (black) and not pre-exposed (red) separately with the SD as error bars. e The mean DAS-28 was depicted for patients pre-exposed to IV abatacept (black) and not pre-exposed (red) separately with the SD as error bars

Back to article page